Obsidian Therapeutics

Obsidian Therapeutics company information, Employees & Contact Information

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients. Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need. Located in the heart of Cambridge with a new laboratory facility in Bedford, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.

Company Details

Employees
94
Founded
-
Address
1030 Massachusetts Avenue,
Phone
(781) 806-6245
Email
in****@****ntx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cambridge, MA
Looking for a particular Obsidian Therapeutics employee's phone or email?

Obsidian Therapeutics Questions

News

Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE - Business Wire

Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE Business Wire

Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb - Investing News Network

Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb Investing News Network

Obsidian Therapeutics Appoints Dr. Madan Jagasia as Chief Executive Officer - citybiz

Obsidian Therapeutics Appoints Dr. Madan Jagasia as Chief Executive Officer citybiz

Obsidian Therapeutics Announces Closing of $115 Million Series B Financing - PR Newswire

Obsidian Therapeutics Announces Closing of $115 Million Series B Financing PR Newswire

Obsidian Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire

Obsidian Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference Business Wire

No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed (NASDAQ:IOVA) - Seeking Alpha

No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed (NASDAQ:IOVA) Seeking Alpha

Obsidian Therapeutics Announces Expansion of Leadership Team - PR Newswire

Obsidian Therapeutics Announces Expansion of Leadership Team PR Newswire

Obsidian Therapeutics Appoints Heidi Hagen to Board of Directors - citybiz

Obsidian Therapeutics Appoints Heidi Hagen to Board of Directors citybiz

Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire

Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire

Top Obsidian Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant